RecruitingPhase 1NCT04928508

Advanced or Recurrent Solid Tumors Treated With SHetA2

Phase 1 Trial of OK-1 (SHetA2) in Patients With Advanced or Recurrent Solid Tumors

Sponsor

University of Oklahoma

Enrollment

50 participants

Start Date

Jul 27, 2022

Study Type

INTERVENTIONAL

Conditions

Solid Tumor, Adult

Summary

The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called OK-1 for people with solid tumor, adult. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOK-1

OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated: 5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg

Locations(1)

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04928508

Related Trials

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT0691575316 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

First In Human Study of CX-2051 in Advanced Solid Tumors

NCT062656888 locations

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

NCT068243631 location

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

NCT049427175 locations